

Embargoed for release until approved by ASA House of Delegates. No part of this document may be released, distributed or reprinted until approved. Any unauthorized copying, reproduction, appropriation or communication of the contents of this document without the express written consent of the American Society of Anesthesiologists is subject to civil and criminal prosecution to the fullest extent possible, including punitive damages.

Practice Advisory for Perioperative Visual Loss Associated with Spine Surgery 2019

An Updated Report by the American Society of Anesthesiologists Task Force on Perioperative Visual Loss

1 PRACTICE advisories are systematically developed reports that are intended to assist decision-making
2 in areas of patient care. Advisories provide a synthesis of scientific literature and analysis of expert opinion,
3 clinical feasibility data, open forum commentary, and consensus surveys. Practice advisories developed by
4 the American Society of Anesthesiologists (ASA) are not intended as standards, guidelines, or absolute
5 requirements, and their use cannot guarantee any specific outcome. They may be adopted, modified, or
6 rejected according to clinical needs and constraints, and they are not intended to replace local institutional
7 policies.

8 Practice advisories summarize the state of the literature and report opinions obtained from expert
9 consultants and ASA members. They are not supported by scientific literature to the same degree as
10 standards or guidelines because of the lack of sufficient numbers of adequately controlled studies. Practice
11 advisories are subject to periodic revision as warranted by the evolution of medical knowledge, technology,
12 and practice.

13 This document updates the “Practice Advisory for Perioperative Visual Loss Associated with Spine
14 Surgery: An Updated Report by the American Society of Anesthesiologists Task Force on Perioperative
15 Visual Loss,” adopted by the ASA in 2011 and published in 2012.*¹

* Updated by the Committee on Standards and Practice Parameters, Jeffrey L. Apfelbaum, M.D. (Committee Chair), Chicago, Illinois; Steven Roth, M.D. (Task Force Co-Chair), Chicago, Illinois; Daniel Rubin, M.D., (Task Force Co-Chair), Chicago, Illinois; Richard T. Connis, Ph.D. (Chief Methodologist), Woodinville, Washington; Madhulika Agarkar, M.P.H. (Methodologist), Schaumburg, Illinois; Paul M. Arnold, M.D., Kansas City, Kansas; Sanjay S. Dhall, M.D., San Francisco, California; Karen B. Domino, M.D., Seattle, Washington; Daniel J. Hoh, M.D., Gainesville, Florida; Steven W. Hwang, M.D., Philadelphia, Pennsylvania; Andrew G. Lee, M.D., Houston, Texas; Lorri A. Lee, M.D., Seattle, Washington; Neil R. Miller, M.D., Baltimore, Maryland; Nancy J. Newman, M.D., Atlanta, Georgia; and Peter J. Savino, M.D., Philadelphia, Pennsylvania; and Michael M. Todd, M.D. Minneapolis, Minnesota.

Received from the American Society of Anesthesiologists, Schaumburg, Illinois. Submitted for publication October __, 2018. Accepted for publication October __ 2018. Supported by the American Society of Anesthesiologists and developed under the direction of the Committee on Standards and Practice Parameters, Jeffrey L. Apfelbaum, M.D. (Chair). Approved by the ASA House of Delegates on October __, 2018. A complete bibliography used to develop this updated Advisory, arranged alphabetically by author, is available as Supplemental Digital Content 1. [Approved by or endorsed by \(add organization names and date of approval/endorsement\).](#)

Address correspondence to the American Society of Anesthesiologists: 1061 American Lane, Schaumburg, Illinois 60173. This Practice Advisory, as well as all published ASA Practice Parameters, may be obtained at no cost through the Journal Web site, www.anesthesiology.org.

16 **Methodology**

17 ***Definition of Perioperative Visual loss***

18 Perioperative visual loss (POVL) after spine surgery is a rare and disabling complication.²⁻⁴ For this
19 Advisory, *perioperative visual loss* refers to permanent impairment or total loss of sight associated with a
20 spine procedure during which general anesthesia is administered. The perioperative period includes the
21 time from the immediate preoperative assessment through discharge from the acute healthcare facility.
22 Conditions addressed in this Advisory include posterior ischemic optic neuropathy (PION), anterior ischemic
23 optic neuropathy (AION), central and branch retinal artery occlusion (RAO), cerebral visual loss (CVL), and
24 posterior reversible encephalopathy syndrome (PRES). AION damages the front of the optic nerve (the
25 optic nerve head or optic disc), whereas PION injures the portion of the optic nerve behind the eye.⁵ “High-
26 risk patients” are defined for this Advisory as those who undergo spine procedures while positioned prone
27 and who have prolonged procedures, experience substantial blood loss, or both.[†]

28 ***Purpose of the Advisory***

29 The purpose of this Advisory is to enhance awareness and reduce the frequency of POVL during and
30 after spine surgery.

31 ***Focus of the Advisory***

32 This Advisory focuses on the perioperative management of patients who are undergoing spine
33 procedures while they are positioned prone and receiving general anesthesia. This Advisory does not
34 address the perioperative management of patients who receive regional anesthesia or sedation. This
35 Advisory also does not include other causes of visual loss. It does not include non-spine surgical
36 procedures (e.g., cardiac surgery, radical neck dissection). In addition, this Advisory does not apply to spine
37 surgery patients younger than 12 years of age.

38 ***Application of the Advisory***

39 This Advisory is intended for use by anesthesiologists, neurosurgeons, neuro-ophthalmologists, and all
40 other individuals who deliver or who are responsible for anesthesia or perioperative care. These individuals
41 may include orthopedic surgeons, neurosurgeons, ophthalmologists, neuro-ophthalmologists, neurologists,
42 nurse anesthetists, perioperative nurses, operating room nurses and anesthesiology assistants. The
43 Advisory also may serve as a resource for other physicians, nurses, and healthcare professionals who
44 manage anesthetized patients.

[†] For the Advisory, prolonged procedures are defined as spine procedures greater than 4 hr. Substantial blood loss is defined as blood loss greater than 800 ml.

45 ***Task Force Members and Consultants***

46 In 2017, the ASA Committee on Standards and Practice Parameters requested that this Advisory be
47 updated. This Advisory update is a revision developed by an ASA-appointed task force of 16 members from
48 various geographic areas of the United States, consisting of 6 anesthesiologists, 4 neuro-ophthalmologists,
49 4 neurosurgeons, and two methodologists. Eight physicians served as official liaisons from national
50 organizations including the North American Neuro-Ophthalmology Society (NANOS), North American Spine
51 Society (NASS), Society for Neuroscience in Anesthesiology and Critical Care (SNACC) and the American
52 Association of Neurological Surgeons (AANS)/ Congress of Neurological Surgeons (CNS) Joint Section on
53 Disorders of the Spine and Peripheral Nerves.

54 The task force developed this Advisory by means of a six-step process. First, criteria for evidence
55 associated with POVL were established. Second, original peer-reviewed published research studies
56 relevant to POVL were reviewed and evaluated. Third, a panel of expert consultants was asked to (a)
57 participate in opinion surveys concerning the effectiveness and safety of various methods and interventions
58 that might be used for prevention of POVL, and (b) review and comment on a draft of the Advisory
59 developed by the task force. Fourth, survey opinions about the Advisory recommendations were solicited
60 from a random sample of active ASA members and participating medical specialty societies. Fifth, the
61 consultants were surveyed to assess their opinions on the feasibility of implementing the advisory. Sixth, all
62 available information was used to build consensus within the task force to finalize the advisory. A summary
63 of recommendations is in Appendix 1.

64 ***Availability and Strength of Evidence***

65 Preparation of this updated advisory followed a rigorous methodological process. Evidence was
66 obtained from two principal sources: scientific evidence and opinion-based evidence

67 ***Scientific Evidence***

68 Scientific evidence used in the development of this advisory is based on cumulative findings from
69 literature published in peer-reviewed journals. Literature citations are obtained from healthcare databases,
70 direct internet searches, task force members, liaisons with other organizations, and manual searches of
71 references located in reviewed articles.

72 Findings from the aggregated literature are reported in the text of this advisory by evidence category,
73 level, and direction. Evidence categories refer specifically to the strength and quality of the research design
74 of the studies. Category A evidence represents results obtained from randomized controlled trials (RCTs),
75 and category B evidence represents observational results obtained from nonrandomized study designs or
76 RCTs without pertinent comparison groups. When available, category A evidence is given precedence over
77 category B evidence for any particular outcome. These evidence categories are divided further into
78 evidence levels. Evidence levels refer specifically to the strength and quality of the summarized study
79 findings (i.e., statistical findings, type of data, and number of studies reporting/replicating the findings). In

80 this document, only the highest level of evidence is included in the summary report for each intervention–
81 outcome pair, including a directional designation of benefit, harm, or equivocality.

82 **Category A.** RCTs report comparative findings between clinical interventions for specified outcomes.
83 Statistically significant ($P < 0.01$) outcomes are designated as either beneficial (B) or harmful (H) for the
84 patient; statistically nonsignificant findings are designated as equivocal (E). †

85 Level 1: The literature contains a sufficient number of RCTs to conduct meta-analysis, and meta-
86 analytic findings from these aggregated studies are reported as evidence.

87 Level 2: The literature contains multiple RCTs, but the number of RCTs is not sufficient to conduct
88 a viable meta-analysis for the purpose of these Guidelines. Findings from these RCTs are reported
89 separately as evidence.

90 Level 3: The literature contains a single RCT, and findings from this study are reported as
91 evidence.

92 **Category B.** Observational studies or RCTs without pertinent comparison groups may permit inference
93 of beneficial or harmful relationships among clinical interventions and clinical outcomes. Inferred findings
94 are given a directional designation of beneficial (B), harmful (H), or equivocal (E). For studies that report
95 statistical findings, the threshold for significance is $P < 0.01$.

96
97 Level 1: The literature contains nonrandomized comparisons (e.g., quasiexperimental, cohort
98 [prospective or retrospective], or case-control research designs) with comparative statistics among
99 clinical interventions for a specified clinical outcome.

100 Level 2: The literature contains noncomparative observational studies with associative statistics
101 (e.g., relative risk, correlation, sensitivity, and specificity).

102 Level 3: The literature contains noncomparative observational studies with descriptive statistics
103 (e.g., frequencies, percentages).

104 Level 4: The literature contains case reports.

105 **Insufficient Literature.** The lack of sufficient scientific evidence in the literature may occur when the
106 evidence is either unavailable (i.e., no pertinent studies found) or inadequate. Inadequate literature cannot
107 be used to assess relationships among clinical interventions and outcomes because a clear interpretation of
108 findings is not obtained due to methodological concerns (e.g., confounding of study design or
109 implementation) or the study does not meet the criteria for content as defined in the “Focus” of the advisory.

110 **Opinion-based Evidence**

111 All opinion-based evidence (e.g., survey data, open forum testimony (from original advisory), internet-
112 based comments, letters, and editorials) relevant to each topic was considered in the development of these

† No relevant studies were found for this Advisory that met the criteria for “Category A” evidence.

113 guidelines. However, only the findings obtained from formal surveys are reported in the document. Opinion
114 surveys were developed by the task force to address each clinical intervention identified in the document.
115 Identical surveys were distributed to expert consultants and a random sample of members of the
116 participating organizations.

117 **Expert and Participating Membership Opinion Surveys.** Survey findings from task force–appointed
118 expert consultants, a random sample of the ASA membership, and membership samples from NANOS,
119 SNACC and AANS/CNS are fully reported in this document. Survey responses were recorded using a 5-
120 point scale and summarized based on median values.

121 Strongly Agree: Median score of 5 (at least 50% of the responses are 5)

122 Agree: Median score of 4 (at least 50% of the responses are 4 or 4 and 5)

123 Equivocal: Median score of 3 (at least 50% of the responses are 3, or no other response category
124 or combination of similar categories contain at least 50% of the responses)

125 Disagree: Median score of 2 (at least 50% of responses are 2 or 1 and 2)

126 Strongly Disagree: Median score of 1 (at least 50% of responses are 1)

127 **Informal Opinion.** Open forum testimony obtained during development of the original advisory,
128 internet-based comments, letters, and editorials are all informally evaluated and discussed during the
129 formulation of guideline recommendations. When warranted, the task force may add educational information
130 or cautionary notes based on this information.

131 **Advisory Evidence and Recommendations**

132 ***Preoperative Patient Evaluation and Preparation***

133 **Literature Findings.** Comparative studies are insufficient to evaluate the impact of conducting an
134 ophthalmic examination. Studies with observational findings indicate that certain conditions, including
135 preoperative anemia, vascular risk factors (e.g., hypertension, diabetes, peripheral vascular disease,
136 coronary artery disease, previous stroke, carotid artery stenosis), obesity, and tobacco use, among other
137 pre-operative characteristics (e.g., age, male sex, and diabetic retinopathy) may be associated with POVL
138 (*Category B2-H evidence*).^{§3,6-10} Two retrospective descriptive studies also indicate that POVL may occur
139 in patients with the above conditions (*Category B3-H evidence*).^{4,11} Case reports indicate that POVL may
140 occur in patients whose medical history includes the above listed preoperative conditions (*Category B4-H*
141 *evidence*^{**}).¹²⁻³⁴ Although a small cup to disc ratio may render the axons of the optic nerve more susceptible
142 to injury, the literature is insufficient to evaluate the role of optic nerve head anatomy as a risk factor for

§ Refer to appendix 2 for details of the literature review and data analyses.

** Note that POVL may still occur in healthy patients without any of the above preoperative conditions.

143 perioperative AION or support routinely conducting a preoperative examination of the cup-to-disc in spine
144 surgery patients.^{5,35} One observational study reported that 86% of patients undergoing spine surgery in the
145 prone position prefer to be informed of the risk of visual loss (*Category B3-B evidence*).³⁶ The literature is
146 insufficient to evaluate whether or not glaucoma is a risk factor for POVL.

147 **Survey Findings.** The consultants and members of ASA, AANS, NANOS and SNACC strongly agree
148 with the recommendation to review a patient’s preoperative history and perform an appropriate examination
149 to identify patients with preoperative conditions such as preoperative anemia, vascular risk factors (*e.g.*,
150 hypertension, diabetes, peripheral vascular disease, coronary artery disease, previous stroke, carotid artery
151 stenosis), obesity, and tobacco use. Consultants and members of the participating organizations agree with
152 the recommendation to inform patients that certain preoperative conditions may increase their risk of POVL
153 in spine surgery. The consultants, members of ASA and NANOS strongly agree, and members of AANS
154 and SNACC agree with the recommendation to inform patients in whom prolonged procedures, substantial
155 blood loss, or both are anticipated that there may be an increased risk of POVL. Finally, consultants and
156 members of ASA, AANS and SNACC agree with the recommendation to determine on a case-by-case basis
157 whether or not to inform patients who are *not* anticipated to be “high-risk” for visual loss; members of
158 NANOS were equivocal.

159 **Advisory Recommendations for Preoperative Patient Evaluation and Preparation**

- 160 • Review a patient’s preoperative history and perform an appropriate examination to identify patients
161 with conditions such as preoperative anemia, vascular risk factors (*e.g.*, hypertension, diabetes,
162 peripheral vascular disease, coronary artery disease, previous stroke, carotid artery stenosis),
163 obesity, and tobacco use.
- 164 • Inform patients that certain preoperative conditions may increase their risk of POVL in spine
165 surgery. These include, but are not limited to those who are male, obese, have vascular disease
166 risk factors such as hypertension and peripheral vascular disease, or have diabetic retinopathy.
- 167 • Inform patients in whom prolonged procedures, substantial blood loss, or both are anticipated that
168 there may be an increased risk of POVL.^{††}
 - 169 ○ Determine on a case-by-case basis whether or not to inform patients who are *not* anticipated to
170 be “high-risk” for visual loss.

171 **Intraoperative Management**

172 Intraoperative management topics consist of (1) blood pressure management, (2) management of blood
173 loss and administration of fluids, (3) use of vasopressors, (4) patient and head positioning, and (5) staging
174 of surgical procedures.

^{††} For the purposes of this Advisory, the Task Force considers such patients (hereafter referred to as “high-risk patients”) to have a higher risk for perioperative visual loss than patients who do not undergo prolonged procedures, have substantial blood loss, or both

175 **Blood Pressure Management**

176 **Literature Findings.** Two retrospective observational studies reported equivocal findings regarding the
 177 association of hypotension and perioperative ION (*Category B2-E evidence*).^{10,11} Case reports indicate
 178 visual loss occurring after procedures in which hypotensive episodes occurred intraoperatively (*Category*
 179 *B4-H evidence*).^{20,21,25,27,34,37-40}

180 Although case reports describe POVL occurring after procedures in which intraoperative hypotension
 181 was deliberately maintained (*i.e.* deliberate hypotension) for patients without hypertension^{18,24,29,41-49} or for
 182 patients with well-controlled chronic hypertension^{18,26,28,29,50,51} (*Category B4-E evidence*), the literature is
 183 equivocal on whether or not the risk of ION is increased due to intraoperative hypotension, either
 184 deliberately induced or due to use of pre-operative anti-hypertensive drugs or intra-operative anesthetics
 185 (*Category B4-E evidence*).^{##}

186 **Survey Findings.** The consultants and members of ASA, AANS, NANOS and SNACC strongly agree with
 187 the recommendation to continually monitor systemic blood pressure in high-risk patients. The consultants
 188 and members of ASA, and SNACC strongly agree and members of AANS and NANOS agree with the
 189 recommendation to and to assess the patient's baseline blood pressure on a case-by-case basis.
 190 Consultants and members of the participating organizations agree with the recommendation to determine
 191 on a case-by case basis if deliberate hypotension should be used in high-risk patients. The consultants and
 192 members of ASA, NANOS and SNACC strongly agree and members of AANS agree with the
 193 recommendation to check for the presence of pre-operative hypertension, its degree of control, the pre-
 194 operative use of anti-hypertensive drugs, and the patient's risk of end-organ damage before using deliberate
 195 hypotension in a high-risk patient.

196 Consultants and members of ASA, AANS, and SNACC strongly agree and members of NANOS agree with
 197 the recommendation to discuss with the surgeon if deliberate hypotension is necessary. Consultants and
 198 members of ASA and SNACC strongly agree and members of AANS and NANOS agree with the
 199 recommendation to maintain arterial pressure at higher levels in hypertensive patients to prevent risks to
 200 end organs. The consultants and members of the participating organizations agree with the
 201 recommendation to use deliberate hypotension in high-risk patients only when the anesthesiologist and
 202 surgeon agree that its use is essential, and strongly agree with the recommendation to treat prolonged
 203 significant decreases in blood pressure.

204 **Management of Blood Loss and Administration of Fluids**

205 **Literature Findings.** Two observational studies report that blood loss and duration of surgery are
 206 associated with POVL (*Category B2-H evidence*).^{8,52} Three descriptive observational studies indicate POVL
 207 may occur with substantial blood loss, prolonged procedures, or both (*Category B3-H evidence*).^{4,11,53} Case

^{##} Because deliberate hypotension can only decrease arterial, and not venous bleeding, it may be of relatively limited utility in patients undergoing spine fusion.

208 reports also describe POVL occurring after prolonged procedures^{12,13,37,43,54-61}, substantial intraoperative
209 blood loss,^{20,21,26,33,41,42,49,62-65} or both^{14-18,23,25,27-29,33,39,40,44,45,47,51,66-71} (*Category B4-H evidence*).^{§§} One case
210 report described POVLs occurring in a spine surgery patient even though the patient's hematocrit was
211 monitored every 1.5 hours throughout the procedure (*Category B4-E evidence*).¹³

212 Although comparative studies are insufficient to evaluate the impact on visual loss of the relative
213 percentages of intraoperatively administered crystalloids and colloids on the occurrence of POVL, one case-
214 control study reported the percent of crystalloid in the total volume replacement had no statistically
215 significant effect on developing ION whereas higher colloid as percent of total nonblood replacement was
216 associated with a reduced risk of developing ION (*Category B2-E evidence*).⁸ Case reports indicate that
217 visual loss still may regardless of the type and relative percentages of fluids used (*Category B4-E*
218 *evidence*).^{15,17,23,25,27,29,30,34,37,39,42,44,45,47,51,64-70}

219 **Survey Findings.** The consultants and members of ASA, AANS and SNACC strongly agree and
220 members of NANOS agree with the recommendation to periodically monitor hemoglobin or hematocrit
221 values during surgery in high-risk patients who experience substantial blood loss. Consultants and
222 members of the participating organizations strongly agree with the recommendation to use transfusions of
223 blood as deemed appropriate. Consultants and members ASA, AANS and SNACC agree with the
224 recommendation that crystalloids or colloids alone, or in combination may be used to maintain adequate
225 replacement or intravascular volume; members of NANOS are equivocal.

226 **Use of Vasopressors**

227 **Literature Findings.** Comparative studies are insufficient to evaluate the relationship of the
228 perioperative administration of high-dose -adrenergic agonists during spine surgery to POVL. One
229 retrospective observational study reported equivocal findings for perioperative vasopressors use when
230 patients with POVL compared with patients without POVL (*Category B2-E evidence*).⁸ One case report
231 indicated that POVL still may occur in spine surgery patients in whom extensive intraoperative hypotension
232 was treated with multiple doses of phenylephrine and ephedrine (*Category B4-E evidence*).³⁴

233 **Survey Findings.** Consultants and members of ASA and SNACC strongly agree and members of
234 AANS and NANOS agree with the recommendation that adrenergic agonists may be used on a case-by-
235 case basis when it is necessary to correct for hypotension.

236 **Patient and Head Positioning Devices**

237 **Literature Findings.** One retrospective study comparing POVL patients with patients without POVL
238 reported a significant association between the use of the Wilson frame and ION (*Category B2-H evidence*).⁸
239 Retrospective observational studies obtained from institutional databases^{***} also describe POVL occurring

^{§§} For this Advisory, prolonged procedures are defined as spine procedures greater than 4 hr. Substantial blood loss is defined as blood loss greater than 800 ml.

^{***} ASA POVL Registry and The Scoliosis Research Society database

240 when a patient is positioned prone on Wilson frame, positioned prone on a Jackson frame, or when the
241 patient's head is supported by various devices such as Mayfield head holder, horseshoe, headrest, tongs,
242 halo, or pillow (*Category B3-H evidence*).^{4,11} ††† Case reports indicate that patient positioning resulting in
243 direct pressure to the eyes (*e.g.*, from the use of a headrest, sheet roll, or other device) may precede the
244 onset of POVL from RAO in spine surgery patients (*Category B4-H evidence*).^{12,21,30,48,49,56,57,60,68,72-75}
245 Comparative studies are insufficient to evaluate if positioning the patient's head below the heart compared
246 with positioning the head in neutral or higher is associated with POVL.

247 Monitoring the eyes during spine surgery may assist in the early identification of eye compression.
248 Although there are a number of head positioning devices that enable the eyes to be checked for
249 compression when the patient is positioned prone, the literature is insufficient to support superiority of any
250 one head positioning device, or to recommend a particular frequency of eye checks.

251 **Survey Findings.** The consultants and members of SNACC strongly agree and members of ASA,
252 AANS and NANOS agree with the recommendation to position the high-risk patient so that the head is level
253 with or higher than the rest of the body when possible. Consultants and members of ASA and SNACC
254 strongly agree and members of AANS and NANOS agree with the recommendation to maintain the high-risk
255 patient's head in a neutral forward position (*e.g.*, without significant neck flexion, extension, lateral flexion, or
256 rotation) when possible. Consultants and members of the participating organizations strongly agree with the
257 recommendation to avoid direct pressure on the eye to prevent RAO. Consultants and members of AANS
258 and SNACC strongly agree and members of ASA and NANOS agree with the recommendation that a head
259 holder may be applied by the spine surgeon in patients in whom head positioning is challenging. Finally,
260 consultants and members of the participating organizations strongly agree with the recommendation to
261 check the position of the eyes periodically during surgery to ensure the head has not moved and there is no
262 eye compression.

263 **Staging of Surgical Procedures**

264 The majority of spine surgery patients who experience perioperative ION undergo prolonged
265 procedures with substantial blood loss while they are positioned prone. Staging of spine surgical
266 procedures involves performing the operative procedure in two or more operations, as opposed to a single
267 surgical procedure.⁷⁶⁻⁷⁹

268 **Literature Findings.** The literature is insufficient to examine the impact of surgical staging on reducing
269 the frequency of POVL in spine surgery patients.

270 **Survey Findings.** The consultants and members of ASA, AANS and SNACC strongly agree and
271 members of NANOS agree with the recommendation that staged spine procedures may be used on a case-
272 by-case basis for high-risk patients.

††† The Task Force believes that there is no pathophysiologic mechanism by which facial edema can cause perioperative ION. There is no evidence that ocular compression causes isolated perioperative anterior ION or posterior ION.

273 **Advisory Recommendations for Intraoperative Management**

274 Blood Pressure Management.

- 275 • Continually^{###} monitor systemic blood pressure in high-risk patients.
 - 276 ○ Assess the patient’s baseline blood pressure on a case-by-case basis.
- 277 • Determine on a case-by case basis if deliberate hypotension should be used in high-risk
278 patients.
 - 279 ○ Check for the presence of pre-operative hypertension, its degree of control, the pre-
280 operative use of anti-hypertensive drugs, and the patient’s risk of end-organ damage before
281 using deliberate hypotension in a high-risk patient.
 - 282 ▪ Discuss with the surgeon if deliberate hypotension is necessary.
 - 283 ○ Maintain arterial pressure at higher levels in hypertensive patients to prevent risks to end
284 organs.
 - 285 ○ Use deliberate hypotension in high-risk patients only when the anesthesiologist and
286 surgeon agree that its use is essential.
 - 287 ▪ Treat prolonged significant decreases in blood pressure.

288 Management of Blood Loss and Administration of Fluids.

- 289 • Periodically monitor hemoglobin or hematocrit values during surgery in high-risk patients who
290 experience substantial blood loss.^{\$\$\$}
 - 291 ○ Use transfusions of blood as deemed appropriate.
 - 292 ○ Crystalloids or colloids alone or in combination may be used to maintain adequate
293 replacement or intravascular volume.

294 Use of Vasopressors.

- 295 • Adrenergic agonists may be used on a case-by-case basis when it is necessary to correct for
296 hypotension.

297 Patient and Head Positioning Devices.

- 298 • Position the high-risk patient so that the head is level with or higher than the rest of the body
299 when possible.
 - 300 ○ Maintain the high-risk patient’s head in a neutral forward position (e.g., without significant
301 neck flexion, extension, lateral flexion, or rotation) when possible.
- 302 • Avoid direct pressure on the eye to prevent RAO.

^{###} Note that “continual” is defined as “repeated regularly and frequently in steady and rapid succession” whereas “continuous” means prolonged without any interruption at any time (from ASA Standards for Basic Anesthetic Monitoring)

^{\$\$\$} The Task Force believes that there is no documented lower limit of hemoglobin concentration that has been associated with the development of perioperative visual loss. Therefore, the Task Force believes a transfusion threshold that would eliminate the risk of perioperative visual loss related to anemia cannot be established at this time.

- 303 ○ A head holder may be applied by the spine surgeon in patients in whom head positioning is
- 304 challenging.
- 305 • Check the position of the eyes periodically during surgery to ensure the head has not moved
- 306 and there is no eye compression.

307 Staging of Surgical Procedures.

- 308 • Staged spine procedures may be used on a case-by-case basis for high-risk patients.

309 ***Postoperative Management***

310 **Literature Findings.** The literature is insufficient to evaluate the effect of assessing a high-risk patient's

311 vision when the patient becomes alert. The literature is insufficient to evaluate the use of magnetic

312 resonance imaging (MRI) or computerized tomography (CT) to rule out intracranial causes of visual loss or

313 the capacity of orbital MRI or CT to detect optic nerve changes in POVL.

314 A case report of one spine surgery patient with bilateral PION indicated that visual recovery occurred

315 after the deliberate maintenance of increased hematocrit and blood pressure (*Category B4-B evidence*).³¹

316 Two case reports indicated that the patients' visual loss improved with the administration of corticosteroids

317 to treat ION (*Category C4-B evidence*)^{59,66}. Fourteen case reports found no visual improvement following the

318 administration of steroids (*Category B4-E evidence*).^{22,29,33,34,40,41,43,57,64,71-73,75} There is insufficient evidence

319 to support the administration of antiplatelet agents or intraocular pressure-lowering agents in the treatment

320 of ION. With respect to perioperative RAO, the literature is insufficient to support the use of any form of

321 treatment.^{****} At this time, there is no evidence of a role for antiplatelet agents, corticosteroids, or

322 intraocular pressure-lowering agents in the management of perioperative ION.

323 **Survey Findings.** The consultants and members of ASA, AANS, NANOS and SNACC agree that for

324 the high-risk patient, conduct an ophthalmological assessment when the patient becomes alert (*e.g.*, in the

325 recovery room, intensive care unit, or nursing floor). Consultants and members of the participating

326 organizations strongly agree with the recommendation that if there is concern regarding potential visual

327 loss, to obtain an urgent ophthalmologic consultation to determine its cause. Consultants strongly agree

328 and members of the participating organizations agree with the recommendation that CT or MRI may be

329 used on a case-by-case basis to rule out intracranial causes of visual loss as well as to visualize an

330 abnormal (*e.g.*, enhancing) optic nerve. Finally, consultants and members of the participating organizations

331 strongly agree with the recommendation that additional management may include optimizing hemoglobin or

332 hematocrit values, hemodynamic status, and arterial oxygenation.

**** The pathogenesis of RAO in this setting is different from patients with spontaneous RAO. Although thrombolysis via catheter in the central retinal artery may dissolve a clot within the early hours after non-perioperative RAO, bleeding in a newly post-operative patient is a potential risk.

333 **Advisory Recommendations for Postoperative Management**

- 334
- For the high-risk patient, conduct an ophthalmological assessment when the patient becomes
335 alert (*e.g.*, in the recovery room, intensive care unit, or nursing floor).
 - If there is concern regarding potential visual loss, obtain an urgent ophthalmologic
336 consultation to determine its cause.
 - CT or MRI may be used on a case-by-case basis to rule out intracranial causes of visual
337 loss as well as to visualize an abnormal (*e.g.*, enhancing) optic nerve.
 - Additional management may include optimizing hemoglobin or hematocrit values,
338 hemodynamic status, and arterial oxygenation.
- 339
- 340
- 341

Appendix 1: Summary of Advisory Statements***Preoperative Patient Evaluation and Preparation***

- Review a patient’s preoperative history and perform an appropriate examination to identify patients with conditions such as preoperative anemia, vascular risk factors (*e.g.*, hypertension, diabetes, peripheral vascular disease, coronary artery disease, previous stroke, carotid artery stenosis), obesity, and tobacco use.
 - Inform patients that certain preoperative conditions may increase their risk of POVL in spine surgery. These include, but are not limited to those who are male, obese, have vascular disease risk factors such as hypertension and peripheral vascular disease, or have diabetic retinopathy.
 - Inform patients in whom prolonged procedures, substantial blood loss, or both are anticipated that there may be an increased risk of POVL.^{†††}
 - Determine on a case-by-case basis whether or not to inform patients who are *not* anticipated to be “high-risk” for visual loss.

Intraoperative Management**Blood Pressure Management.**

- Continually^{†††} monitor systemic blood pressure in high-risk patients.
 - Assess the patient’s baseline blood pressure on a case-by-case basis.
- Determine on a case-by case basis if deliberate hypotension should be used in high-risk patients.
 - Check for the presence of pre-operative hypertension, its degree of control, the pre-operative use of anti-hypertensive drugs, and the patient’s risk of end-organ damage before using deliberate hypotension in a high-risk patient.
 - Discuss with the surgeon if deliberate hypotension is necessary.
 - Maintain arterial pressure at higher levels in hypertensive patients to prevent risks to end organs.
 - Use deliberate hypotension in high-risk patients only when the anesthesiologist and surgeon agree that its use is essential.
 - Treat prolonged significant decreases in blood pressure.

††† For the purposes of this Advisory, the Task Force considers such patients (hereafter referred to as “high-risk patients”) to have a higher risk for perioperative visual loss than patients who do not undergo prolonged procedures, have substantial blood loss, or both

†††† Note that “continual” is defined as “repeated regularly and frequently in steady and rapid succession” whereas “continuous” means prolonged without any interruption at any time (from ASA Standards for Basic Anesthetic Monitoring)

Management of Blood Loss and Administration of Fluids.

- Periodically monitor hemoglobin or hematocrit values during surgery in high-risk patients who experience substantial blood loss.^{§§§§}
 - Use transfusions of blood as deemed appropriate.
 - Crystalloids or colloids alone or in combination may be used to maintain adequate replacement or intravascular volume.

Use of Vasopressors.

- Adrenergic agonists may be used on a case-by-case basis when it is necessary to correct for hypotension.

Patient and Head Positioning Devices.

- Position the high-risk patient so that the head is level with or higher than the rest of the body when possible.
 - Maintain the high-risk patient's head in a neutral forward position (e.g., without significant neck flexion, extension, lateral flexion, or rotation) when possible.
- Avoid direct pressure on the eye to prevent RAO.
 - A head holder may be applied by the spine surgeon in patients in whom head positioning is challenging.
- Check the position of the eyes periodically during surgery to ensure the head has not moved and there is no eye compression.

Staging of Surgical Procedures.

- Staged spine procedures may be used on a case-by-case basis for high-risk patients.

Postoperative Management

- For the high-risk patient, conduct an ophthalmological assessment when the patient becomes alert (e.g., in the recovery room, intensive care unit, or nursing floor).
 - If there is concern regarding potential visual loss, obtain an urgent ophthalmologic consultation to determine its cause.
 - CT or MRI may be used on a case-by-case basis to rule out intracranial causes of visual loss as well as to visualize an abnormal (e.g., enhancing) optic nerve.
 - Additional management may include optimizing hemoglobin or hematocrit values, hemodynamic status, and arterial oxygenation.

Appendix 2: Methods and Analyses

342 For this updated practice advisory, a systematic search and review of peer reviewed published literature
343 was conducted, with scientific findings summarized and reported below and in the document. Assessment
344 of conceptual issues, and the practicality and feasibility of the advisory recommendations was also
345 evaluated, with opinion data collected from surveys and other sources. Both the systematic literature review
346 and the opinion data are based on evidence linkages, or statements regarding potential relationships
347 between interventions and outcomes associated with POVL associated with a spine procedure during which
348 general anesthesia is administered and permanent impairment or total loss of sight occurs. The evidence

^{§§§§} The Task Force believes that there is no documented lower limit of hemoglobin concentration that has been associated with the development of perioperative visual loss. Therefore, the Task Force believes a transfusion threshold that would eliminate the risk of perioperative visual loss related to anemia cannot be established at this time.

349 linkage interventions are listed below.***** The evidence model below guided the search, providing inclusion
350 and exclusion information regarding patients, procedures, practice settings, providers, clinical interventions,
351 and outcomes. The ASA Committee on Standards and Practice Parameters reviews all practice guidelines
352 at the ASA annual meeting and determines update and revision timelines. The policy of the ASA Committee
353 on Standards and Practice Parameters is to update practice guidelines every 5 yr.

Evidence Model

354 Patients

- 355 • Inclusion criteria:
 - 356 ○ Patients undergoing back or spine surgery
 - 357 ○ Patients positioned prone
 - 358 ○ Patients receiving general anesthesia
- 359 • Exclusion criteria:
 - 360 ○ Children younger than 12 years
 - 361 ○ Patients not positioned prone

362 Procedures

- 363 • Inclusion criteria:
 - 364 ○ Back surgery
 - 365 ○ Spine surgery
- 366 • Exclusion criteria:
 - 367 ○ Procedures where anesthetic care is not provided
 - 368 ○ Non-supine surgical procedures
 - 369 ▪ Cardiac surgery
 - 370 ▪ Radical neck dissection
 - 371 ▪ Ocular surgery
 - 372 ▪ Intracranial procedures

373 Practice Settings

- 374 • Inclusion criteria:
 - 375 ○ Any health care facility
 - 376 ▪ Medical centers
 - 377 ▪ Hospitals
 - 378 ▪ Operating room
 - 379 ▪ Spine surgery postop nursing unit
 - 380 ▪ Other anesthetizing locations
 - 381 ▪ Recovery rooms (PACU)
 - 382 ▪ Intensive care units (ICU)
 - 383 ▪ Outpatient procedural units
 - 384 ▪ Office-based practices
- 385 • Exclusion criteria:
 - 386 ○ Non-perioperative settings

387 Providers

- 388 • Inclusion criteria:
 - 389 ○ All anesthesia providers
 - 390 ▪ Anesthesiologists
 - 391 ▪ Providers working under the direction of anesthesiologists
 - 392 ▪ Orthopedic surgeons

***** Unless otherwise specified, outcomes for the listed interventions refer to the occurrence of perioperative visual loss.

- 393 ▪ Neuro-ophthalmologists
- 394 ▪ Neurologists
- 395 ▪ Nurse anesthetists
- 396 ▪ Perioperative nurses

- 397 • Exclusion criteria:
- 398 ○ Individuals who do not evaluate or care for patients undergoing surgery, nor consult on them

399 **Interventions**

- 400 • Preoperative Evaluation.
- 401 ○ Ophthalmic or neuro-ophthalmic evaluation for high-risk patients or procedures^{††††}
- 402 ○ Informing patients of the risk of POVL in spine surgery
- 403 ○ Determine acceptable blood pressure according to patient's preoperative history (i.e.,
- 404 hypertensive patients at risk)

- 405 • Preoperative Preparation.
- 406 ○ Pharmacologic methods to reduce increased intraocular pressure (i.e., use of topical beta
- 407 blockers)
- 408 ○ Alpha 2 agonists to protect the optic nerve (e.g., dexmedetomidine)
- 409 ○ Mild deliberate hypothermia to protect the optic nerve (by maintaining temperature 34 C)

- 410 • Intraoperative Management.
- 411 ○ Blood pressure.
- 412 ▪ Continual^{‡‡‡‡} monitoring of blood pressure to avoid hypotension^{§§§§§}

- 413 ○ Blood Loss and Administration of Fluids.
- 414 ▪ Continual monitoring of hydration levels to avoid over hydration
- 415 ▪ Fluid replacement limitation
- 416 ▪ Colloids (e.g., albumin, hetastarch) *versus* crystalloids (e.g., saline, lactated ringer's) to
- 417 maintain optimal levels of hydration
- 418 ▪ Periodic monitoring of hemoglobin/hematocrit values during surgery in high-risk patients
- 419 who experience substantial blood loss.

- 420 ○ Patient Positioning.
- 421 ▪ Avoidance of direct pressure on the globe of the eye
- 422 ▪ Positioning the patient so that the head is level with or higher than the heart
- 423 ▪ Maintaining of face in a neutral forward position (e.g., without significant neck flexion or
- 424 extension, lateral flexion, or rotation)

- 425 ○ Surgical procedures.
- 426 ▪ Use of staged procedures for spine surgery when anticipated length is greater than 6 hours
- 427

†††† For this Advisory, prolonged procedures are defined as spine procedures greater than 4 hr. Substantial blood loss is defined as blood loss greater than 800 ml.

‡‡‡‡ Note that “continual” is defined as “repeated regularly and frequently in steady and rapid succession” whereas “continuous” means prolonged without any interruption at any time (from ASA Standards for Basic Anesthetic Monitoring)

§§§§§ Hypotension is defined as mean pressures < 20% below baseline, or systolic BP < 90 mm Hg despite surgical incision

- 428 • Postoperative Management.
- 429 ○ Assess patient's visual status for loss of vision
- 430 ○ Assess visual evoked potentials to detect optic nerve dysfunction
- 431 ○ Begin initial treatment (e.g., increase blood pressure and hemoglobin/hematocrit if appropriate,
- 432 administer supplemental oxygen, antiplatelet drugs, aspirin, or steroids)

433 **Outcomes**

- 434 • Inclusion criteria:
- 435 ○ Perioperative visual loss (POVL)
- 436 ▪ Posterior ischemic optic neuropathy (PION)
- 437 ▪ Anterior ischemic optic neuropathy (AION)
- 438 ▪ Central and branch retinal artery occlusion (RAO)
- 439 ▪ Posterior reversible encephalopathy syndrome (PRES)
- 440 ▪ Cerebral visual loss (CVL)

- 441 • Exclusion criteria:
- 442 ○ Non-perioperative visual loss
- 443 ○ Acute angle-closure glaucoma
- 444 ○ Retinal detachment
- 445 ○ Vitreous hemorrhage

446 **Guideline goals**

- 447 • To reduce the frequency of POVL
- 448 • To enhance awareness of the potential for POVL
- 449 • To benefit patients by reducing the risk of visual loss.
- 450 • To help guide those caring for these patients in preventing and identifying the problem

451 **Evidence collection**

- 452 • Literature inclusion criteria:
- 453 ○ Randomized controlled trials
- 454 ○ Prospective nonrandomized comparative studies (e.g., quasi-experimental, cohort)
- 455 ○ Retrospective comparative studies (e.g., case-control)
- 456 ○ Observational studies (e.g., correlational or descriptive statistics)
- 457 ○ Case reports, case series
- 458 • Literature exclusion criteria (except to obtain new citations):
- 459 ○ Editorials
- 460 ○ Literature reviews
- 461 ○ Meta-analyses
- 462 ○ Abstracts greater than 5 years old
- 463 ○ Unpublished studies
- 464 ○ Studies in non-peer reviewed journals
- 465 ○ Newspaper articles
- 466 • Survey evidence:
- 467 ○ Expert consultant survey
- 468 ○ ASA membership survey
- 469 ○ Other participating organization surveys
- 470 ○ Reliability survey
- 471 ○ Feasibility survey

472 **State of the Literature.** For the systematic review, potentially relevant clinical studies were identified
473 via electronic and manual searches. Healthcare database searches included PubMed, EMBASE, Web of
474 Science, Google Books, and the Cochrane Central Register of Controlled Trials. The searches covered a

475 6.5-yr period from January 1, 2012, through June 1, 2018. Accepted studies from the previous advisory
476 were also re-reviewed, covering the period of January 1, 2002, through December 31, 2011. Only studies
477 containing original findings from peer-reviewed journals were acceptable. Editorials, letters, and other
478 articles without data were excluded. A literature search strategy and PRISMA^{*****} flow diagram is available
479 as Supplemental Digital Content 2, <http://links.lww.com/ALN/XXXXXX>.

480 In total, 569 new citations were identified, with 484 articles assessed for eligibility. After review, 452 were
481 excluded, with 32 new studies meeting the above stated criteria. These studies were combined with 48 pre-
482 2012 articles used in the previous advisory and 5 provided by task force members, resulting in a total of 85
483 articles accepted as evidence for these guidelines. In this document, 79 are referenced, with a complete
484 bibliography of articles used to develop these guidelines, organized by section, available as Supplemental
485 Digital Content 3, <http://links.lww.com/ALN/XXXXXXXX>.

486 Each pertinent outcome reported in a study was classified by evidence category and level and
487 designated as beneficial, harmful, or equivocal. Findings were then summarized for each evidence linkage
488 and reported in the text of the updated Advisory, with evidence tables available as Supplemental Digital
489 Content 4, <http://links.lww.com/ALN/XXXXXX>.

490 Interobserver agreement among task force members and two methodologists was obtained by interrater
491 reliability testing of 33 randomly selected studies. Agreement levels using a κ statistic for two-rater
492 agreement pairs were as follows: (1) research design, $\kappa = 0.64$ to 0.94 ; (2) type of analysis, $\kappa = 0.62$ to 1.00 ;
493 (3) evidence linkage assignment, $\kappa = 0.66$ to 0.81 ; and (4) literature inclusion for database, $\kappa = 0.27$ to 1.00 .
494 Three-rater κ values were: (1) research design, $\kappa = 0.76$; (2) type of analysis, $\kappa = 0.74$; (3) linkage
495 assignment, $\kappa = 0.74$; and (4) literature database inclusion, $\kappa = 0.33$. These values represent moderate to
496 high levels of agreement.

497 ***Consensus-based Evidence***

498 Consensus was obtained from multiple sources, including: (1) survey opinion from consultants⁺⁺⁺⁺⁺ who
499 were selected based on their knowledge or expertise in moderate procedural sedation and analgesia; (2)
500 survey opinions from a randomly selected sample of active members of the ASA, AANS, NANOS, and
501 SNACC; (3) testimony from attendees of publicly held open forums for the original advisory at a national
502 anesthesia meeting⁺⁺⁺⁺⁺; (4) internet commentary; and (5) task force opinion and interpretation. The survey
503 rate of return was 50% ($n = 35$ of 70) for consultants. For membership respondents, survey data were
504 collected from 259 ASA members, 103 AANS members, 119 NANOS members, and 57 SNACC members.
505 The results of the surveys are reported in tables 1–4 and are summarized in the text of the advisory.

506 For the Feasibility survey, consultants were asked to indicate which, if any, of the evidence linkages
507 would change their clinical practices if the guidelines were instituted. The rate of return was ___% ($n = _$ of

***** Preferred reporting items of systematic reviews and meta-analyses

+++++ Consultants were drawn from the following specialties where perioperative visual loss is a concern:
anesthesiology, ophthalmology, orthopedic surgery, and neurosurgery.

+++++ Society for Ambulatory Anesthesia 14th Annual Meeting, Seattle, Washington, April 30, 1999.

508 ____). The percent of responding consultants expecting *no change* associated with each linkage were as
 509 follows (___%): preoperative evaluation – ___%; preoperative preparation – ___%; blood pressure
 510 monitoring – ___%; fluid management – ___%; management of blood loss – ; patient positioning – ___%;
 511 surgical procedures – ___%; and postoperative management – ___%. ___ respondents (___%) indicated
 512 that the guidelines would have *no effect* on the amount of time spent on a typical case with the
 513 implementation of these guidelines. ___ respondents (___%) indicated that there would be an increase in
 514 the amount of time, with ___ of these respondents estimating an increase ranging from __ to __ min. ___
 515 respondents (___%) estimated a decrease in the amount of time they would spend on a typical case.

Research Support

Support was provided solely from institutional and/or departmental sources in the American Society of Anesthesiologists. Dr. Roth receives funding from the National Institutes of Health Grant EY 027447 to Dr. Roth.

Competing Interests

The authors declare no competing interests. Drs. Roth, Newman and Todd have provided expert witness evaluation and testimony in cases of POVL on behalf of patients, physicians, and hospitals.

Correspondence

Address correspondence to the American Society of Anesthesiologists: 1061 American Lane, Schaumburg, Illinois 60173. These updated Practice Guidelines, and all ASA Practice Parameters, may be obtained at no cost through the journal Web site, www.anesthesiology.org.

References

1. Practice advisory for perioperative visual loss associated with spine surgery: An updated report by the American Society of Anesthesiologists task force on perioperative visual loss. *Anesthesiology* 2012; 116:274-85
2. Emery SE, Daffner SD, France JC, Ellison M, Grose BW, Hobbs GR, Clovis NB: Effect of head position on intraocular pressure during lumbar spine fusion: A randomized, prospective study. *J Bone Joint Surg Am* 2015; 97:1817-23
3. Nandyala SV, Marquez-Lara A, Fineberg SJ, Singh R, Singh K: Incidence and risk factors for perioperative visual loss after spinal fusion. *Spine J* 2014; 14:1866-72
4. Shillingford JN, Laratta JL, Sarpong NO, Swindell H, Cerpa M, Lehman RA, Lenke LG, Fischer C: Visual loss following spine surgery: What have we seen within the scoliosis research society morbidity and mortality database? *Spine* 2018
5. Biousse V, Newman NJ: Ischemic Optic Neuropathies. *N Engl J Med* 2015; 372:2428-36
6. Calway T, Rubin DS, Moss HE, Joslin CE, Mehta AI, Roth S: Perioperative retinal artery occlusion: incidence and risk factors in spinal fusion surgery from the US national inpatient sample 1998–2013. *J Neuroophthalmol* 2018; 38:36-41
7. De la Garza-Ramos R, Samdani AF, Sponseller PD, Ain MC, Miller NR, Shaffrey CI, Sciubba DM: Visual loss after corrective surgery for pediatric scoliosis: incidence and risk factors from a nationwide database. *Spine J* 2016; 16:516-22
8. Lee LA, Roth S, Todd MM, Posner KL, Polissar NL, Neradilek MB, Torner J, Newman NJ, Domino KB, Lauer KK, Buddithi R, Gollapudy S, Pajewski TN, Scalzo DC, Avitsian R, Brown MJ, Buenvenida S, Mashour GA, Moore LE, Samra SK, Lieberman J, Lane RK, Ramani R, Wagner J,

- Tempelhoff R, Monsey CM, Robicsek SA, Vu MM, Weeks J, Manninen PH, Fu ES, Sanchez-Yanes GC, Peterfreund RA, Albrecht MA, Sapire KJ, Baughman VL, Caplan RA, Cheney FW, Metzner J: Risk factors associated with ischemic optic neuropathy after spinal fusion surgery. *Anesthesiology* 2012; 116: 15-24
9. Patil CG, Lad EM, Lad SP, Ho C, Boakye M: Visual loss after spine surgery: A population-based study. *Spine (Phila Pa 1976)* 2008; 33:1491-6
 10. Rubin DS, Parakati I, Lee LA, Moss HE, Joslin CE, Roth S: Perioperative visual loss in spine fusion surgery: ischemic optic neuropathy in the United States from 1998 to 2012 in the nationwide inpatient sample. *Anesthesiology* 2016; 125:457-64
 11. Lee LA, Roth S, Posner KL, Cheney FW, Caplan RA, Newman NJ, Domino KB: The American Society of Anesthesiologists Postoperative Visual Loss Registry: Analysis of 93 spine surgery cases with postoperative visual loss. *Anesthesiology* 2006; 105:652-9
 12. Amorim Correa JL, Acioly MA: The the enigma of orbital compartment syndrome after lumbar spine surgery in the prone position: Case report and literature review. *World Neurosurg* 2018; 110: 309-14
 13. Agarwal N, Hansberry DR, Goldstein IM: Cortical blindness following posterior lumbar decompression and fusion. *J Clin Neurosci* 2014; 21:155-9
 14. Alexandrakis G, Lam BL: Bilateral posterior ischemic optic neuropathy after spinal surgery. *Am J Ophthalmol* 1999; 127:354-5
 15. Bojinova RI, Konieczka K, Todorova MG: Unilateral loss of vision after spinal surgery in a patient with flammer syndrome. *Klin Monatsbl Augenheilkd* 2016; 233:429-31
 16. Chung MS, Son JH: Visual loss in one eye after spinal surgery. *Korean J Ophthalmol* 2006; 20:139-42
 17. Dilger JA, Tetzlaff JE, Bell GR, Kosmorsky GS, Agnor RC, O'Hara JF, Jr.: Ischaemic optic neuropathy after spinal fusion. *Can J Anaesth* 1998; 45:63-6
 18. Dunker S, Hsu HY, Sebag J, Sadun AA: Perioperative risk factors for posterior ischemic optic neuropathy. *J Am Coll Surg* 2002; 194:705-10
 19. Goni V, Tripathy SK, Goyal T, Tamuk T, Panda BB, Bk S: Cortical blindness following spinal surgery: very rare cause of perioperative vision loss. *Asian Spine J* 2012; 6:287-90
 20. Hoff JM, Varhaug P, Midelfart A, Lund-Johansen M: Acute visual loss after spinal surgery. *Acta Ophthalmol* 2010; 88:490-92
 21. Jampol LM, Goldbaum M, Rosenberg M, Bahr R: Ischemia of ciliary arterial circulation from ocular compression. *Arch Ophthalmol* 1975; 93:1311-7
 22. Kasodekar VB, Chen JL: Monocular blindness: a complication of intraoperative positioning in posterior cervical spine surgery. *Singapore Med J* 2006; 47:631-3
 23. Katz DA, Karlin LI: Visual field defect after posterior spine fusion. *Spine (Phila Pa 1976)* 2005; 30: E83-5
 24. Katz DM, Trobe JD, Cornblath WT, Kline LB: Ischemic optic neuropathy after lumbar spine surgery. *Arch Ophthalmol* 1994; 112:925-31
 25. Kueper J, Loftus ML, Boachie-Adjei O, Lebl D: Posterior reversible encephalopathy syndrome: Temporary visual loss after spinal deformity surgery. *Am J Orthop (Belle Mead NJ)* 2015; 44:E465-8
 26. Lee AG: Ischemic optic neuropathy following lumbar spine surgery. Case report. *J Neurosurg* 1995; 83:348-9
 27. Reddy A, Foroozan R, Edmond JC, Hinckley LK: Dilated superior ophthalmic veins and posterior ischemic optic neuropathy after prolonged spine surgery. *J Neuroophthalmol* 2008; 28:327-8
 28. Ripart J, Desmots JM: Loss of vision after anaesthesia for nonophthalmic surgery: A persistent problem. *Eur J Anaesthesiol* 2009; 26:524-6
 29. Roth S, Nunez R, Schreider BD: Unexplained visual loss after lumbar spinal fusion. *J Neurosurg Anesthesiol* 1997; 9:346-8
 30. Roth S, Tung A, Ksiazek S: Visual loss in a prone-positioned spine surgery patient with the head on a foam headrest and goggles covering the eyes: An old complication with a new mechanism. *Anesth Analg* 2007; 104:1185-7
 31. Stevens WR, Glazer PA, Kelley SD, Lietman TM, Bradford DS: Ophthalmic complications after spinal surgery. *Spine (Phila Pa 1976)* 1997; 22:1319-24
 32. Yilmaz M, Kalemci O: Visual loss after lumbar discectomy due to cortical infarction: Case report. *J Neurol Sci* 2013; 30:422-26
 33. Yu YH, Chen WJ, Chen LH, Chen WC: Ischemic orbital compartment syndrome after posterior spinal surgery. *Spine (Phila Pa 1976)* 2008; 33:E569-72

34. Zimmerer S, Koehler M, Turtschi S, Palmowski-Wolfe A, Girard T: Amaurosis after spine surgery: Survey of the literature and discussion of one case. *Eur Spine J* 2011; 20:171-6
35. Beck RW, Servais GE, Hayreh SS: Anterior ischemic optic neuropathy. IX. Cup-to-disc ratio and its role in pathogenesis. *Ophthalmology* 1987; 94:1503-8
36. Corda DM, Dexter F, Pasternak JJ, Trentman TL, Nottmeier EW, Brull SJ: Patients' perspective on full disclosure and informed consent regarding postoperative visual loss associated with spinal surgery in the prone position. *Mayo Clin Proc* 2011; 86:865-8
37. Akpinar E, Gurbuz MS, Bitirgen G, Okutan MO: Unilateral vision loss without ophthalmoplegia as a rare complication of spinal surgery. *J Neurosci Rural Pract* 2017; 8:288-90
38. Hollenhorst RW, Svien HJ, Benoit CF: Unilateral blindness occurring during anesthesia for neurosurgical operations. *Arch Ophthalmol* 1954; 52:819-30
39. Kim JW, Hills WL, Rizzo JF, Egan RA, Lessell S: Ischemic optic neuropathy following spine surgery in a 16-year-old patient and a ten-year-old patient. *J Neuroophthalmol* 2006; 26:30-3
40. Mishra RK, Mahajan C, Bindra A, Goyal K: Postoperative visual loss following dorsal root entry zone rhizotomy: A dreaded complication after a benign procedure. *Saudi J Anaesth* 2016; 10:449-52
41. Bradish CF, Flowers M: Central retinal artery occlusion in association with osteogenesis imperfecta. *Spine (Phila Pa 1976)* 1987; 12:193-4
42. Brown RH, Schauble JF, Miller NR: Anemia and hypotension as contributors to perioperative loss of vision. *Anesthesiology* 1994; 80:222-6
43. Chalam KV, Shah VA: Severe bilateral posterior ischemic optic neuropathy as a complication of spinal surgery. *Eye (Lond)* 2005; 19:367-8
44. Kamming D, Clarke S: Postoperative visual loss following prone spinal surgery. *Br J Anaesth* 2005; 95:257-60
45. Lee LA, Lam AM: Unilateral blindness after prone lumbar spine surgery. *Anesthesiology* 2001; 95:793-5
46. Montero JA, Ruiz-Moreno JM, Galindo A, Fernandez-Munoz M: Release hallucinations and visual loss as first manifestations of postoperative unilateral blindness. *Eur J Ophthalmol* 2007; 17:844-6
47. Murphy MA: Bilateral posterior ischemic optic neuropathy after lumbar spine surgery. *Ophthalmology* 2003; 110:1454-7
48. Sys J, Michielsen J, Mertens E, Verstreken J, Tassignon MJ: Central retinal artery occlusion after spinal surgery. *Eur Spine J* 1996; 5:74-5
49. Wolfe SW, Lospinuso MF, Burke SW: Unilateral blindness as a complication of patient positioning for spinal surgery. a case report. *Spine (Phila Pa 1976)* 1992; 17:600-5
50. Pin-On P, Boonsri S: Postoperative visual loss in orthopedic spine surgery in the prone position: a case report. *J Med Assoc Thai* 2015; 98:320-4
51. Stang-Veldhouse KN, Yeu E, Rothenberg DM, Mizen TR: Unusual presentation of perioperative ischemic optic neuropathy following major spine surgery. *J Clin Anesth* 2010; 22:52-5
52. Farag E, Abd-Elseyed AA, Dalton JE, Nada E, Parker BM: Postoperative vision loss after spine surgery: a single-institution case-control comparison. *Ochsner J* 2014; 14:179-83
53. Cheng MA, Sigurdson W, Tempelhoff R, Laurysen C: Visual loss after spine surgery: A survey. *Neurosurgery* 2000; 46:625-30
54. Kumar N, Jivan S, Topping N, Morrell AJ: Blindness and rectus muscle damage following spinal surgery. *Am J Ophthalmol* 2004; 138:889-91
55. Leibovitch I, Casson R, Laforest C, Selva D: Ischemic orbital compartment syndrome as a complication of spinal surgery in the prone position. *Ophthalmology* 2006; 113:105-8
56. Locastro A, Novak KD, Biglan AW: Central retinal artery occlusion in a child after general anesthesia. *Am J Ophthalmol* 1991; 112:91-2
57. Mertens E, Smets RM, Sys J, Michielsen J, Verstreken J, Tassignon MJ: Central retinal artery occlusion after back surgery: A case report. *Bull Soc Belge Ophtalmol* 1995; 255:127-31
58. Nathan ST, Jain V, Lykissas MG, Crawford AH, West CE: Transient cortical blindness as a complication of posterior spinal surgery in a pediatric patient. *J Pediatr Orthop B* 2013; 22:416-9
59. Shifa J, Abebe W, Bekele N, Habte D: A case of bilateral visual loss after spinal cord surgery. *Pan Afr Med J* 2016; 23:119
60. Grossman W, Ward WT: Central retinal artery occlusion after scoliosis surgery with a horseshoe headrest. Case report and literature review. *Spine (Phila Pa 1976)* 1993; 18:1226-8

61. West J, Askin G, Clarke M, Vernon SA: Loss of vision in one eye following scoliosis surgery. *Br J Ophthalmol* 1990; 74:243-4
62. Bermejo-Alvarez MA, Carpintero M, Garcia-Carro G, Acebal G, Fervienza P, Cosio F: Ischemic optic neuropathy after lumbar spine surgery. *Rev Esp Anesthesiol Reanim* 2007; 54:621-5
63. Huber JF, Grob D: Bilateral cortical blindness after lumbar spine surgery. A case report. *Spine (Phila Pa 1976)* 1998; 23:1807-9
64. Mohan K, Rawall S, Nene A: Visual loss after spine surgery. *Indian J Orthop* 2012; 46:106-8
65. Ibrahim TF, Sweis RT, Nockels RP: Reversible postoperative blindness caused by bilateral status epilepticus amauroticus following thoracolumbar deformity correction: Case report. *J Neurosurg Spine* 2017; 27:63-7
66. Hassani V, Homaei MM, Shahbazi A, Zamani MM, Safari S, Nadi S, Rahimizadeh A, Lashkari MH, Alizadeh Zendehtood S: Human erythropoietin effect in postoperative visual loss following spine surgery: A case report. *Anesth Pain Med* 2014; 4:e7291
67. Katzman SS, Moschonas CG, Dzioba RB: Amaurosis secondary to massive blood loss after lumbar spine surgery. *Spine (Phila Pa 1976)* 1994; 19:468-9
68. Nakra D, Bala I, Pratap M: Unilateral postoperative visual loss due to central retinal artery occlusion following cervical spine surgery in prone position. *Paediatr Anaesth* 2007; 17:805-8
69. Quraishi NA, Wolinsky JP, Gokaslan ZL: Transient bilateral post-operative visual loss in spinal surgery. *Eur Spine J* 2012; 21 Suppl 4:S495-8
70. Samdani AF, Rutter L, Betz RR, Mulcahey MJ: Vision loss after spinal fusion for scoliosis in a child with spinal cord injury. *J Spinal Cord Med* 2009; 32:591-4
71. Lee SH, Chung I, Choi DS, Shin IW, Kim S, Kang S, Kim JY, Chung YK, Sohn JT: Visual loss due to optic nerve infarction and central retinal artery occlusion after spine surgery in the prone position: A case report. *Medicine (Baltimore)* 2017; 96:e7379
72. Bekar A, Tureyen K, Aksoy K: Unilateral blindness due to patient positioning during cervical syringomyelia surgery: Unilateral blindness after prone position. *J Neurosurg Anesthesiol* 1996; 8:227-9
73. Hoski JJ, Eismont FJ, Green BA: Blindness as a complication of intraoperative positioning. A case report. *J Bone Joint Surg Am* 1993; 75:1231-2
74. Ooi EI, Ahem A, Zahidin AZ, Bastion ML: Unilateral visual loss after spine surgery in the prone position for extradural haematoma in a healthy young man. *BMJ Case Rep* 2013; doi: 10.1136/bcr-2013-200632
75. Raj A, Arya SK, Sood S: Unilateral visual loss due to central retinal artery occlusion with total ophthalmoplegia following cervical spine surgery in prone position. *Nepal J Ophthalmol* 2015; 7:191-3
76. Edwards CC, 2nd, Lessing NL, Ford L, Edwards CC: Deep vein thrombosis after complex posterior spine surgery: Does staged surgery make a difference? *Spine Deform* 2018; 6:141-7
77. Passias PG, Poorman GW, Jalai CM, Line B, Diebo B, Park P, Hart R, Burton D, Schwab F, Lafage V, Bess S, Errico T: Outcomes of open staged corrective surgery in the setting of adult spinal deformity. *Spine J* 2017; 17:1091-99
78. Maddox JJ, Pruitt DR, Agel J, Bransford RJ: Unstaged versus staged posterior-only thoracolumbar fusions in deformity: A retrospective comparison of perioperative complications. *Spine J* 2014; 14:1159-65
79. Hassanzadeh H, Gjolaj JP, El Dafrawy MH, Jain A, Skolasky RL, Cohen DB, Kebaish KM: The timing of surgical staging has a significant impact on the complications and functional outcomes of adult spinal deformity surgery. *Spine J* 2013; 13:1717-22

Table 1. Expert Consultant Survey Results (Response Rate = 51%)

Recommendations	Answer Rate N (%)	Strongly Agree (%)	Agree (%)	Equivocal (%)	Disagree (%)	Strongly Disagree (%)
<i>Preoperative patient evaluation and preparation</i>						
Review a patient's preoperative history and perform an appropriate examination to identify patients with conditions such as preoperative anemia, vascular risk factors (e.g., hypertension, diabetes, peripheral vascular disease, coronary artery disease, previous stroke, carotid artery stenosis), obesity, and tobacco use.	35 (97)	83*	14	3	0	0
Inform patients that certain preoperative conditions may increase their risk of POVL in spine surgery. These include, but are not limited to those who are male, obese, have vascular disease risk factors such as hypertension and peripheral vascular disease, or have diabetic retinopathy.	35 (97)	40	46*	11	0	0
Inform patients in whom prolonged procedures, substantial blood loss, or both are anticipated that there may be an increased risk of POVL.	35 (97)	69*	20	11	0	0
Determine on a case-by-case basis whether or not to inform patients who are not anticipated to be "high-risk" for visual loss.	35 (97)	31	31*	17	20	0
<i>Intraoperative blood pressure management</i>						
Continually monitor systemic blood pressure in high-risk patients.	34 (94)	82*	9	9	0	0
Assess the patient's baseline blood pressure on a case-by-case basis.	33 (92)	67*	33	0	0	0
Determine on a case-by case basis whether deliberate hypotension should be used in high-risk patients.	34 (94)	44	15*	3	3	35
Check for the presence of pre-operative hypertension, its degree of control, the pre-operative use of anti-hypertensive drugs, and the patient's risk of end-organ damage before using deliberate hypotension in a high-risk patient.	34 (94)	71*	12	9	3	6
Discuss with the surgeon whether deliberate hypotension is necessary.	34 (94)	68*	15	3	6	9
Maintain arterial pressure at higher levels in hypertensive patients to prevent risks to end organs.	33 (92)	64*	21	15	0	0
Use deliberate hypotension in high-risk patients only when the anesthesiologist and surgeon agree that its use is essential despite employing other means to minimize bleeding.	35 (97)	37	34*	6	6	17
Treat prolonged significant decreases in blood pressure.	34 (94)	91*	9	0	0	0
Adrenergic agonists may be used on a case-by-case basis when it is necessary to correct for hypotension.	33 (92)	58*	39	3	0	0
<i>Intraoperative patient and head position devices and surgical staging</i>						
Periodically monitor hemoglobin or hematocrit values during surgery in high-risk patients who experience substantial blood loss.	35 (97)	89*	9	3	0	0
Use transfusions of blood as deemed appropriate.	35 (97)	83*	17	0	0	0
Crystalloids or colloids alone or in combination may be used to maintain adequate replacement or intravascular volume.	35 (97)	29	*34	23	9	6
Position the high-risk patient so that the head is level with or higher than the heart when possible.	35 (97)	49*	34	9	9	0

Maintain the high-risk patient's head in a neutral forward position (e.g., without significant neck flexion, extension, lateral flexion, or rotation) when possible.	33 (92)	67*	30	3	0	0
Avoid direct pressure on the eye to prevent retinal artery occlusion (RAO).	34 (94)	88*	12	0	0	0
A head holder may be applied by the spine surgeon in patients in whom head positioning is challenging.	35 (97)	63*	31	6	0	0
Check the position of the eyes periodically during surgery to ensure the head has not moved and there is no eye compression.	35 (97)	91*	9	0	0	0
Staged spine procedures may be used on a case-by-case basis for high-risk patients.	34 (94)	65*	32	3	0	0

Postoperative management

For the high-risk patient, conduct an ophthalmological assessment when the patient becomes alert (e.g., in the recovery room, intensive care unit, or nursing floor).	35 (97)	34	17*	29	20	0
If there is concern regarding potential visual loss, obtain an urgent ophthalmologic consultation to determine its cause.	34 (94)	82*	18	0	0	0
CT or MRI may be used on a case-by-case basis to rule out intracranial causes of visual loss as well as to visualize an abnormal (e.g., enhancing) optic nerve.	34 (94)	50*	32	18	0	0
Additional management may include optimizing hemoglobin or hematocrit values, hemodynamic status, and arterial oxygenation.	35 (97)	63*	29	9	0	0

*Median

Table 2. ASA Member Survey Results (Response Rate = 5%)

Recommendations	Answer Rate N (%)	Strongly Agree (%)	Agree (%)	Equivocal (%)	Disagree (%)	Strongly Disagree (%)
Preoperative patient evaluation and preparation						
Review a patient's preoperative history and perform an appropriate examination to identify patients with conditions such as preoperative anemia, vascular risk factors (e.g., hypertension, diabetes, peripheral vascular disease, coronary artery disease, previous stroke, carotid artery stenosis), obesity, and tobacco use.	258 (99)	73*	24	3	0	0
Inform patients that certain preoperative conditions may increase their risk of POVL in spine surgery. These include, but are not limited to those who are male, obese, have vascular disease risk factors such as hypertension and peripheral vascular disease, or have diabetic retinopathy.	259 (100)	42	39*	15	3	1
Inform patients in whom prolonged procedures, substantial blood loss, or both are anticipated that there may be an increased risk of POVL.	257 (99)	52*	35	11	2	1
Determine on a case-by-case basis whether or not to inform patients who are not anticipated to be "high-risk" for visual loss.	256 (98)	18	43*	19	14	5
Intraoperative blood pressure management						
Continually monitor systemic blood pressure in high-risk patients.	236 (91)	67*	23	8	1	0
Assess the patient's baseline blood pressure on a case-by-case basis.	234 (90)	53*	29	3	11	4

Determine on a case-by case basis whether deliberate hypotension should be used in high-risk patients.	236 (91)	44	26*	7	14	9
Check for the presence of pre-operative hypertension, its degree of control, the pre-operative use of anti-hypertensive drugs, and the patient's risk of end-organ damage before using deliberate hypotension in a high-risk patient.	235 (90)	73*	23	1	2	1
Discuss with the surgeon whether deliberate hypotension is necessary.	236 (91)	73*	24	1	0	2
Maintain arterial pressure at higher levels in hypertensive patients to prevent risks to end organs.	237 (91)	60*	31	7	2	0
Use deliberate hypotension in high-risk patients only when the anesthesiologist and surgeon agree that its use is essential despite employing other means to minimize bleeding.	235 (90)	49	29*	8	7	7
Treat prolonged significant decreases in blood pressure.	236 (91)	86*	14	0	0	0
Adrenergic agonists may be used on a case-by-case basis when it is necessary to correct for hypotension.	233 (90)	60*	36	2	2	0
<i>Intraoperative patient and head position devices and surgical staging</i>						
Periodically monitor hemoglobin or hematocrit values during surgery in high-risk patients who experience substantial blood loss.	228 (88)	73*	23	4	0	0
Use transfusions of blood as deemed appropriate.	226 (87)	71*	28	1	0	0
Crystalloids or colloids alone or in combination may be used to maintain adequate replacement or intravascular volume.	226 (87)	31	43*	19	6	1
Position the high-risk patient so that the head is level with or higher than the heart when possible.	222 (85)	32	43*	21	2	1
Maintain the high-risk patient's head in a neutral forward position (e.g., without significant neck flexion, extension, lateral flexion, or rotation) when possible.	220 (85)	62*	33	4	0	0
Avoid direct pressure on the eye to prevent retinal artery occlusion (RAO).	219 (84)	84*	16	0	0	0
A head holder may be applied by the spine surgeon in patients in whom head positioning is challenging.	222 (85)	43	50*	6	0	0
Check the position of the eyes periodically during surgery to ensure the head has not moved and there is no eye compression.	221 (85)	78*	20	1	0	0
Staged spine procedures may be used on a case-by-case basis for high-risk patients.	219 (84)	58*	33	8	0	0
<i>Postoperative management</i>						
For the high-risk patient, conduct an ophthalmological assessment when the patient becomes alert (e.g., in the recovery room, intensive care unit, or nursing floor).	218 (84)	22	39*	28	9	2
If there is concern regarding potential visual loss, obtain an urgent ophthalmologic consultation to determine its cause.	219 (84)	68*	29	2	0	0
CT or MRI may be used on a case-by-case basis to rule out intracranial causes of visual loss as well as to visualize an abnormal (e.g., enhancing) optic nerve.	217 (83)	34	48*	17	1	0
Additional management may include optimizing hemoglobin or hematocrit values, hemodynamic status, and arterial oxygenation.	217 (83)	61*	37	2	0	0

*Median

Table 3. AANS Member Survey Results (Response Rate = %)

Recommendations	Answer Rate N (%)	Strongly Agree (%)	Agree (%)	Equivocal (%)	Disagree (%)	Strongly Disagree (%)
<i>Preoperative patient evaluation and preparation</i>						
Review a patient's preoperative history and perform an appropriate examination to identify patients with conditions such as preoperative anemia, vascular risk factors (e.g., hypertension, diabetes, peripheral vascular disease, coronary artery disease, previous stroke, carotid artery stenosis), obesity, and tobacco use.	103 (99)	53*	34	11	1	1
Inform patients that certain preoperative conditions may increase their risk of POVL in spine surgery. These include, but are not limited to those who are male, obese, have vascular disease risk factors such as hypertension and peripheral vascular disease, or have diabetic retinopathy.	103 (99)	29	37*	27	7	0
Inform patients in whom prolonged procedures, substantial blood loss, or both are anticipated that there may be an increased risk of POVL.	103 (99)	35	41*	16	9	0
Determine on a case-by-case basis whether or not to inform patients who are not anticipated to be "high-risk" for visual loss.	101 (97)	18	40*	17	17	9
<i>Intraoperative blood pressure management</i>						
Continually monitor systemic blood pressure in high-risk patients.	89 (85)	69*	28	2	0	1
Assess the patient's baseline blood pressure on a case-by-case basis.	87 (84)	33	46*	9	7	5
Determine on a case-by case basis whether deliberate hypotension should be used in high-risk patients.	88 (85)	24	27*	18	18	13
Check for the presence of pre-operative hypertension, its degree of control, the pre-operative use of anti-hypertensive drugs, and the patient's risk of end-organ damage before using deliberate hypotension in a high-risk patient.	87 (84)	49	28*	17	2	3
Discuss with the surgeon whether deliberate hypotension is necessary.	82 (79)	57*	27	11	5	0
Maintain arterial pressure at higher levels in hypertensive patients to prevent risks to end organs.	86 (83)	35	38*	24	1	1
Use deliberate hypotension in high-risk patients only when the anesthesiologist and surgeon agree that its use is essential despite employing other means to minimize bleeding.	85 (82)	33	36*	14	12	5
Treat prolonged significant decreases in blood pressure.	86 (83)	74*	22	3	0	0
Adrenergic agonists may be used on a case-by-case basis when it is necessary to correct for hypotension.	86 (83)	34	51*	15	0	0
<i>Intraoperative patient and head position devices and surgical staging</i>						
Periodically monitor hemoglobin or hematocrit values during surgery in high-risk patients who experience substantial blood loss.	82 (79)	57*	32	11	0	0
Use transfusions of blood as deemed appropriate.	80 (77)	63*	35	3	0	0
Crystalloids or colloids alone or in combination may be used to maintain adequate replacement or intravascular volume.	78 (75)	27	37*	21	12	4
Position the high-risk patient so that the head is level with or higher than the heart when possible.	78 (75)	44	35*	19	3	0

Maintain the high-risk patient's head in a neutral forward position (e.g., without significant neck flexion, extension, lateral flexion, or rotation) when possible.	79 (76)	47	42*	9	3	0
Avoid direct pressure on the eye to prevent retinal artery occlusion (RAO).	78 (75)	82*	14	4	0	0
A head holder may be applied by the spine surgeon in patients in whom head positioning is challenging.	79 (76)	65*	32	4	0	0
Check the position of the eyes periodically during surgery to ensure the head has not moved and there is no eye compression.	78 (75)	67*	28	5	0	0
Staged spine procedures may be used on a case-by-case basis for high-risk patients.	78 (75)	50*	41	8	1	0

Postoperative management

For the high-risk patient, conduct an ophthalmological assessment when the patient becomes alert (e.g., in the recovery room, intensive care unit, or nursing floor).	77 (74)	22	39*	18	16	5
If there is concern regarding potential visual loss, obtain an urgent ophthalmologic consultation to determine its cause.	77 (74)	66*	30	4	0	0
CT or MRI may be used on a case-by-case basis to rule out intracranial causes of visual loss as well as to visualize an abnormal (e.g., enhancing) optic nerve.	77 (74)	34	47*	18	1	0
Additional management may include optimizing hemoglobin or hematocrit values, hemodynamic status, and arterial oxygenation.	78 (75)	54*	38	8	0	0

*Median

Table 4. NANOS Member Survey Results (Response Rate = %)

Recommendations	Answer Rate N (%)	Strongly Agree (%)	Agree (%)	Equivocal (%)	Disagree (%)	Strongly Disagree (%)
Preoperative patient evaluation and preparation						
Review a patient's preoperative history and perform an appropriate examination to identify patients with conditions such as preoperative anemia, vascular risk factors (e.g., hypertension, diabetes, peripheral vascular disease, coronary artery disease, previous stroke, carotid artery stenosis), obesity, and tobacco use.	119 (99)	55*	40	4	0	0
Inform patients that certain preoperative conditions may increase their risk of POVL in spine surgery. These include, but are not limited to those who are male, obese, have vascular disease risk factors such as hypertension and peripheral vascular disease, or have diabetic retinopathy.	118 (98)	40	42*	15	3	1
Inform patients in whom prolonged procedures, substantial blood loss, or both are anticipated that there may be an increased risk of POVL.	118 (98)	54*	42	3	2	0
Determine on a case-by-case basis whether or not to inform patients who are not anticipated to be "high-risk" for visual loss.	118 (98)	15	33	31*	17	4
Intraoperative blood pressure management						
Continually monitor systemic blood pressure in high-risk patients.	109 (91)	64*	32	4	0	0
Assess the patient's baseline blood pressure on a case-by-case basis.	108 (90)	27	41*	11	18	4

Determine on a case-by case basis whether deliberate hypotension should be used in high-risk patients.	109 (91)	38	35*	16	11	1
Check for the presence of pre-operative hypertension, its degree of control, the pre-operative use of anti-hypertensive drugs, and the patient's risk of end-organ damage before using deliberate hypotension in a high-risk patient.	109 (91)	57*	34	7	1	1
Discuss with the surgeon whether deliberate hypotension is necessary.	108 (90)	44	37*	13	4	2
Maintain arterial pressure at higher levels in hypertensive patients to prevent risks to end organs.	105 (88)	20	48*	31	1	0
Use deliberate hypotension in high-risk patients only when the anesthesiologist and surgeon agree that its use is essential despite employing other means to minimize bleeding.	109 (91)	35	51*	13	1	0
Treat prolonged significant decreases in blood pressure.	109 (91)	51*	43	6	0	0
Adrenergic agonists may be used on a case-by-case basis when it is necessary to correct for hypotension.	108 (90)	15	55*	28	2	1
<i>Intraoperative patient and head position devices and surgical staging</i>						
Periodically monitor hemoglobin or hematocrit values during surgery in high-risk patients who experience substantial blood loss.	106 (88)	42	44*	11	3	0
Use transfusions of blood as deemed appropriate.	106 (88)	52*	44	4	0	0
Crystalloids or colloids alone or in combination may be used to maintain adequate replacement or intravascular volume.	106 (88)	16	33	29*	20	2
Position the high-risk patient so that the head is level with or higher than the heart when possible.	98 (82)	29	42*	23	6	0
Maintain the high-risk patient's head in a neutral forward position (e.g., without significant neck flexion, extension, lateral flexion, or rotation) when possible.	100 (83)	37	45*	17	1	0
Avoid direct pressure on the eye to prevent retinal artery occlusion (RAO).	99 (83)	86*	13	1	0	0
A head holder may be applied by the spine surgeon in patients in whom head positioning is challenging.	101 (84)	33	50*	17	1	0
Check the position of the eyes periodically during surgery to ensure the head has not moved and there is no eye compression.	103 (86)	63*	35	2	0	0
Staged spine procedures may be used on a case-by-case basis for high-risk patients.	101 (84)	29	48*	23	1	0
<i>Postoperative management</i>						
For the high-risk patient, conduct an ophthalmological assessment when the patient becomes alert (e.g., in the recovery room, intensive care unit, or nursing floor).	101 (84)	22	37*	26	14	2
If there is concern regarding potential visual loss, obtain an urgent ophthalmologic consultation to determine its cause.	102 (85)	71*	27	2	0	0
CT or MRI may be used on a case-by-case basis to rule out intracranial causes of visual loss as well as to visualize an abnormal (e.g., enhancing) optic nerve.	103 (86)	32	54*	13	1	0
Additional management may include optimizing hemoglobin or hematocrit values, hemodynamic status, and arterial oxygenation.	103 (86)	61*	34	5	0	0

*Median

Table 5. SNACC Member Survey Results (Response Rate = %)

Recommendations	Answer Rate N (%)	Strongly Agree (%)	Agree (%)	Equivocal (%)	Disagree (%)	Strongly Disagree (%)
<i>Preoperative patient evaluation and preparation</i>						
Review a patient's preoperative history and perform an appropriate examination to identify patients with conditions such as preoperative anemia, vascular risk factors (e.g., hypertension, diabetes, peripheral vascular disease, coronary artery disease, previous stroke, carotid artery stenosis), obesity, and tobacco use.	55 (96)	67*	25	4	4	0
Inform patients that certain preoperative conditions may increase their risk of POVL in spine surgery. These include, but are not limited to those who are male, obese, have vascular disease risk factors such as hypertension and peripheral vascular disease, or have diabetic retinopathy.	56 (98)	30	36*	21	11	2
Inform patients in whom prolonged procedures, substantial blood loss, or both are anticipated that there may be an increased risk of POVL.	56 (98)	46	36*	14	2	2
Determine on a case-by-case basis whether or not to inform patients who are not anticipated to be "high-risk" for visual loss.	57 (100)	25	51*	11	7	7
<i>Intraoperative blood pressure management</i>						
Continually monitor systemic blood pressure in high-risk patients.	46 (81)	85*	13	2	0	0
Assess the patient's baseline blood pressure on a case-by-case basis.	47 (82)	55*	23	2	9	11
Determine on a case-by-case basis whether deliberate hypotension should be used in high-risk patients.	48 (84)	44	17*	6	21	13
Check for the presence of pre-operative hypertension, its degree of control, the pre-operative use of anti-hypertensive drugs, and the patient's risk of end-organ damage before using deliberate hypotension in a high-risk patient.	47 (82)	74*	17	2	4	2
Discuss with the surgeon whether deliberate hypotension is necessary.	48 (84)	71*	17	2	10	0
Maintain arterial pressure at higher levels in hypertensive patients to prevent risks to end organs.	49 (86)	65*	31	4	0	0
Use deliberate hypotension in high-risk patients only when the anesthesiologist and surgeon agree that its use is essential despite employing other means to minimize bleeding.	47 (82)	40	28*	13	13	6
Treat prolonged significant decreases in blood pressure.	48 (84)	100*	0	0	0	0
Adrenergic agonists may be used on a case-by-case basis when it is necessary to correct for hypotension.	47 (82)	64*	32	4	0	0
<i>Intraoperative patient and head position devices and surgical staging</i>						
Periodically monitor hemoglobin or hematocrit values during surgery in high-risk patients who experience substantial blood loss.	47 (82)	74*	26	0	0	0
Use transfusions of blood as deemed appropriate.	47 (82)	68*	30	0	2	0
Crystalloids or colloids alone or in combination may be used to maintain adequate replacement or intravascular volume.	47 (82)	45	36*	9	11	0
Position the high-risk patient so that the head is level with or higher than the heart when possible.	47 (82)	57*	26	15	2	0

Maintain the high-risk patient's head in a neutral forward position (e.g., without significant neck flexion, extension, lateral flexion, or rotation) when possible.	47 (82)	70*	30	0	0	0
Avoid direct pressure on the eye to prevent retinal artery occlusion (RAO).	47 (82)	87*	13	0	0	0
A head holder may be applied by the spine surgeon in patients in whom head positioning is challenging.	46 (81)	59*	37	4	0	0
Check the position of the eyes periodically during surgery to ensure the head has not moved and there is no eye compression.	47 (82)	79*	19	0	2	0
Staged spine procedures may be used on a case-by-case basis for high-risk patients.	46 (81)	57*	37	7	0	0

Postoperative management

For the high-risk patient, conduct an ophthalmological assessment when the patient becomes alert (e.g., in the recovery room, intensive care unit, or nursing floor).	47 (82)	26	40*	19	15	0
If there is concern regarding potential visual loss, obtain an urgent ophthalmologic consultation to determine its cause.	46 (81)	78*	20	0	2	0
CT or MRI may be used on a case-by-case basis to rule out intracranial causes of visual loss as well as to visualize an abnormal (e.g., enhancing) optic nerve.	47 (82)	38	47*	15	0	0
Additional management may include optimizing hemoglobin or hematocrit values, hemodynamic status, and arterial oxygenation.	47 (82)	53*	40	6	0	0

***Median**